Wednesday, June 02, 2021 7:37:43 PM
I honestly think we are going to see a steady rise and an eventual new high similar to early February when we first hit .30
I think by the end of next week or middle of the week after that we possibly anywhere from .43-.50, mostly on anticipation of things to come but also on this recent patent news. The first run up to .30 started around the patent extension news on 2/2 and steadily climbed over the next 1-2 weeks. I think in part it was because of patent news, but more because of all the other news catalysts on the horizon. It feels like a very similar situation, except instead of leading to the beginning of mice trials, we are now leading to the end results and potential begining of human testing, more possible funding as well as paying off debt and possibly some elucidation of a timeline to bring one or both treatment drugs (cancer, covid) to market.
All my opinion, and it could take longer to get to that .43 target range, but we could shoot right past it depending on the kind of news a d developments we get this month.
I think by the end of next week or middle of the week after that we possibly anywhere from .43-.50, mostly on anticipation of things to come but also on this recent patent news. The first run up to .30 started around the patent extension news on 2/2 and steadily climbed over the next 1-2 weeks. I think in part it was because of patent news, but more because of all the other news catalysts on the horizon. It feels like a very similar situation, except instead of leading to the beginning of mice trials, we are now leading to the end results and potential begining of human testing, more possible funding as well as paying off debt and possibly some elucidation of a timeline to bring one or both treatment drugs (cancer, covid) to market.
All my opinion, and it could take longer to get to that .43 target range, but we could shoot right past it depending on the kind of news a d developments we get this month.
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
